Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells.
Novel models of autochthonous tumorigenesis and adoptive T cell therapy (ATT) are providing new clues regarding the pro-tumorigenic and immunosuppressive effects of myeloid-derived suppressor cells (MDSC), and their interaction with T cells. New findings are shifting the perception of the main level at which MDSC act, from direct cell-to-cell suppression to others, such as limiting T cell infiltration. Adoptively transferred, high-avidity T cells recognizing peptides with high-affinity for MHC-I eliminated large tumors. However, low-avidity T cells or low-affinity peptides resulted in failure to eradicate tumors. Manipulation of intratumoral myeloid cells improved the outcome of otherwise unsuccessful ATT. Therefore, therapeutic intervention directed at the tumor stroma might be required when using suboptimal T cells for ATT.
Department of Radiation and Cellular Oncology, The Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA. Electronic address: aarina@bsd.uchicago.edu.
Ainhoa
A
Arina
Verona University Hospital, Department of Pathology and Diagnostics, 37134 Verona, Italy. Electronic address: vincenzo.bronte@univr.it.
Vincenzo
V
Bronte
D019264:Adoptive Transfer; D000818:Animals; D002450:Cell Communication / Q000276:immunology*; D006801:Humans; D056747:Immunomodulation; D016219:Immunotherapy, Adoptive / Q000379:methods; D022423:Myeloid Cells / Q000276:immunology* / Q000378:metabolism*; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D016896:Treatment Outcome; D059016:Tumor Microenvironment